Turin, 18 June 2020 _ We are pleased to announce that Dr. Vincent Metzler has joined the Board of Directors of Kither Biotech, to support the operational team in developing and implementing the clinical, regulatory and commercial development plans of the company’s proprietary assets in rare pulmonary diseases.
“We continue to strengthen our board with expertise in support of our strategic focus on advancing our pipeline, as we progress toward clinical trials” states Laura Iris Ferro, Chairman of the Board of Kither Biotech.
Overall Vincent brings over 20 years of commercial experience in the international top-pharma and biotech industry, covering the areas of supportive care, targeted therapies, cell therapies and orphan drugs in various therapeutic areas.
Since January 2019, Vincent has hold the position of Head of Marketing and Commercial Operations for Europe at Atara Biotherapeutics, a US company focused on the development of T cell-based immunotherapies in cancer and viral diseases. Prior to that, he was member of the Executive Leadership Team of Wilson Therapeutics, a Swedish biotech company in early clinical development phase. He played a pivotal role in the M&A activities that led to the acquisition of Wilson Therapeutics by Alexion Pharmaceuticals in 2018, through a public cash offer corresponding to a total company value of approx. USD 855 million.
Earlier, Vincent held commercial leadership positions at Alexion Pharmaceuticals and various marketing & sales positions at Miltenyi Biotec GmbH, F. Hoffmann-La Roche Ltd, Amgen Inc. and Idexx Laboratories.
Kither Biotech – Kither Biotech is a biopharma company founded by Prof. Emilio Hirsch, Prof. Alberto Bardelli and Marco Kevin Malisani. The company aims to identify and develop new drug candidates for the treatment of pulmonary diseases, with specific focus on cystic fibrosis and idiopathic pulmonary fibrosis. Kither Biotech is a spin-off from the University of Turin and actively collaborates with the Molecular Biotechnology Center (University of Turin) and other research centres in the world. In July 2019, Kither Biotech raised a €5.6m financing round to support the clinical development of his new drug for cystic fibrosis and other pulmonary diseases. Moreover, the company developed a pipeline of treatments currently under preclinical development, with programs in asthma, COPD, idiopathic pulmonary fibrosis and other therapeutic areas